2024
Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV
Miller E, McGinnis K, Edelman E, Feinberg T, Gordon K, Kerns R, Marshall B, Patterson J, McRae M. Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV. AIDS And Behavior 2024, 28: 3994-4004. PMID: 39264485, PMCID: PMC11586311, DOI: 10.1007/s10461-024-04494-w.Peer-Reviewed Original ResearchMental health classesSubstance use disordersOpioid use disorderHIV statusBuprenorphine initiationVeterans Aging Cohort StudyInitiate buprenorphineMental health diagnosesAging Cohort StudyBuprenorphine treatmentMultiple pain conditionsAssociated with HIV statusInfluence treatment retentionUse disorderTreatment of opioid use disorderHigher comorbidity burdenAge of patientsClinical encountersMental healthHealth diagnosisBlack veteransHealth classesLatent class analysisCohort studyPrescription dataMultidisciplinary proactive e-consults to improve guideline-directed medical therapies for patients with diabetes and chronic kidney disease: an implementation study
Rikin S, Bauman L, Arnaoudova I, DiPalo K, Suda N, Gupta S, Deng Y, Golestaneh L. Multidisciplinary proactive e-consults to improve guideline-directed medical therapies for patients with diabetes and chronic kidney disease: an implementation study. BMJ Open Diabetes Research & Care 2024, 12: e004155. PMID: 38719510, PMCID: PMC11085711, DOI: 10.1136/bmjdrc-2024-004155.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGuideline AdherenceHumansMaleMiddle AgedPatient Care TeamPilot ProjectsPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CarePrognosisReferral and ConsultationRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsConceptsGuideline-directed medical therapyE-consultationImprove guideline-directed medical therapySystem-level barriersPatient-specific barriersHealth system strategiesElectronic health recordsAcademic health systemRenin-angiotensin-aldosterone system inhibitorsChronic kidney diseasePrescribed guideline-directed medical therapySodium-glucose cotransporter-2 inhibitorsE-consult recommendationElectronic consultationIn-depth interviewsPreliminary effectivenessHealth recordsHealth systemImplementation studyOvercome barriersType 2 diabetesMonths postbaselineMultidisciplinary teamPrescription dataAdministrative support
2023
US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021
Elmarasi M, Fuehrlein B. US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021. Exploratory Research In Clinical And Social Pharmacy 2023, 13: 100392. PMID: 38149102, PMCID: PMC10750172, DOI: 10.1016/j.rcsop.2023.100392.Peer-Reviewed Original ResearchMajor depressive disorderMonoamine oxidase inhibitorsTricyclic antidepressantsDepressive disorderCommon mental health concernsStudy periodClasses of antidepressantsMedicaid programUS Medicaid programMental health conditionsSerious mental health conditionsPublic health systemMental health concernsAntidepressant prescriptionsSingle antidepressantTreatment patternsAntidepressant usagePrescription dataMedicaid dataUS adultsAntidepressantsHealth complicationsLifetime diagnosisOxidase inhibitorsHealth system
2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology 2022, 4: e490-e506. PMID: 35698725, PMCID: PMC9179144, DOI: 10.1016/s2665-9913(22)00098-4.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesCOVID-19-related deathsSevere COVID-19 outcomesImmune-modifying therapiesCritical care admissionInflammatory diseasesCOVID-19 outcomesImmune-modifying drugsHospital admissionGeneral populationCare admissionHazard ratioStandard systemic therapyStandard systemic treatmentSevere COVID-19Primary care recordsPrimary care dataNon-white ethnic groupsCohort studySystemic therapySystemic treatmentCox regressionPrescription dataCare recordsWhite ethnic group
2020
Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa
Caturegli G, Materi J, Lombardo A, Milovanovic M, Yende N, Variava E, Golub J, Martinson N, Hoffmann C. Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa. Public Health Action 2020, 10: 118-123. PMID: 33134126, PMCID: PMC7577007, DOI: 10.5588/pha.20.0020.Peer-Reviewed Original ResearchIsoniazid preventive therapy prescriptionIsoniazid preventive therapyPrescribing toolsStreamlining documentationMixed-methods implementation studyIsoniazid preventive therapy implementationIsoniazid preventive therapy initiationSame-day antiretroviral therapyPrimary care clinicsAntiretroviral therapyTB preventive therapyPreventive therapyLimited management supportPatient-related factorsAntiretroviral therapy initiationCare clinicsProvider acceptanceImplementation studyQualitative interviewsWHO targetPrescribingPrescription dataPrescribed deviceStock-outsProviders
2000
Using a Computer Database to Monitor Compliance With Pharmacotherapeutic Guidelines for Schizophrenia
Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA. Using a Computer Database to Monitor Compliance With Pharmacotherapeutic Guidelines for Schizophrenia. Psychiatric Services 2000, 51: 791-794. PMID: 10828112, DOI: 10.1176/appi.ps.51.6.791.Peer-Reviewed Original ResearchConceptsPatient Outcomes Research TeamAcute episodePrescription dataSchizophrenia Patient Outcomes Research TeamVeterans Affairs Medical CenterTrial of clozapinePercent of patientsFirst-line treatmentPatient prescription dataPharmacotherapeutic guidelinesPharmacotherapeutic recommendationsAdequate trialConventional antipsychoticsConventional medicationsConventional regimensOutpatient visitsAntipsychotic regimenTreatment recommendationsSymptom episodesMedical CenterPatientsClozapineConventional drugsComputerized databasePORT recommendations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply